Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice
Open accessThe DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.
Abstract
Hyperglycaemia causes endothelial dysfunction, which is the initial process in the development of diabetic vascular complications. Upon injury, endothelial cells undergo an endothelial-to-mesenchymal transition (EndMT), lose their specific marker, and gain mesenchymal phenotypes. This study investigated the effect of liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, on EndMT inhibition and neointima formation in diabetic mice induced by streptozotocin. The diabetic mice with a wire-induced vascular injury in the right carotid artery were treated with or without liraglutide for four weeks. The degree of neointima formation and re-endothelialisation was evaluated by histological assessments. Endothelial fate tracing revealed that endothelium-derived cells contribute to neointima formation through EndMT in vivo. In the diabetic mouse model, liraglutide attenuated wire injury-induced neointima formation and accelerated re-endothelialisation. In vitro, a high glucose condition (30 mmol/L) triggered morphological changes and mesenchymal marker expression in human umbilical vein endothelial cells (HUVECs), which were attenuated by liraglutide or Activin receptor-like 5 (ALK5) inhibitor SB431542. The inhibition of AMP-activated protein kinase (AMPK) signaling by Compound C diminished the liraglutide-mediated inhibitory effect on EndMT. Collectively, liraglutide was found to attenuate neointima formation in diabetic mice partially through EndMT inhibition, extending the potential therapeutic role of liraglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In streptozotocin-induced diabetic mice, liraglutide treatment for 28 days was found to inhibit high glucose and interleukin (IL)-1β-induced EndMT in endothelial cells and consequently attenuate neointima formation via activation of the AMPK pathway, which was evidenced by a reduction of the expression of mesenchymal markers such as smooth muscle 22α (SM22α), vimentin, and Snail [51].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“Liraglutide is a long-acting analogue of a glucagon-like peptide 1 (GLP-1) receptor agonist and is used for lowering blood glucose in patients with diabetes [17].”
BackgroundInfluentialDiabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I
Paneni, F., Beckman, J. A., Creager, M. A., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht149 · Cited by 1,401
Endothelial dysfunction — A major mediator of diabetic vascular disease
Sena, C. M., Pereira, A. M., & Seiça, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.006 · Cited by 797
Endothelial to Mesenchymal Transition in Cardiovascular Disease
Kovacic, J. C., Dimmeler, S., Harvey, R. P., Finkel, T., Aikawa, E., Krenning, G., & Baker, A. H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.089 · Cited by 631
Evrard, S. M., Lecce, L., Michelis, K. C., Nomura-Kitabayashi, A., Pandey, G., Purushothaman, K.-R., d’Escamard, V., Li, J. R., Hadri, L., Fujitani, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11853 · Cited by 620
Endothelial-to-mesenchymal transition drives atherosclerosis progression
Chen, P.-Y., Qin, L., Baeyens, N., Li, G., Afolabi, T., Budatha, M., Tellides, G., Schwartz, M. A., & Simons, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82719 · Cited by 588
Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders
Piera-Velazquez, S., Li, Z., & Jimenez, S. A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.001 · Cited by 580
Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications
Tabit, C. E., Chung, W. B., Hamburg, N. M., & Vita, J. A. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9134-4 · Cited by 572
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“Recently, a GLP-1 agonist has been found to attenuate atherosclerotic lesions and endothelial function by inhibiting the inflammation process [18,19].”
BackgroundTGF-β Signaling Mediates Endothelial-to-Mesenchymal Transition (EndMT) During Vein Graft Remodeling
Cooley, B. C., Nevado, J., Mellad, J., Yang, D., St. Hilaire, C., Negro, A., Fang, F., Chen, G., San, H., Walts, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3006927 · Cited by 392
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage
Choi, K. J., Nam, J.-K., Kim, J.-H., Choi, S., & Lee, Y. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0439-4 · Cited by 120
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“In streptozotocin-induced diabetic mice, liraglutide treatment for 28 days was found to inhibit high glucose and interleukin (IL)-1β-induced EndMT in endothelial cells and consequently attenuate neointima formation via activation of the AMPK pathway, which was evidenced by a reduction of the expression of mesenchymal…”
BackgroundResearch progress of endothelial‐mesenchymal transition in diabetic kidney disease
Chen, Y., Zou, H., Lü, H., Xiang, H., & Chen, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17356 · Cited by 72
Self-citationHullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 59
GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02124-w · Cited by 47
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Endothelial-to-mesenchymal transition: An underappreciated mediator of diabetic complications
Wang, E., Wang, H., & Chakrabarti, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1050540 · Cited by 51
Wei, L., Mo, W., Lan, S., Yang, H., Huang, Z., Liang, X., Li, L., Xian, J., Xie, X., Qin, Y., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1861940 · Cited by 48
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
Pearson, S. M., Kietsiriroje, N., & Ajjan, R. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s229802 · Cited by 38
Valero‐Muñoz, M., Oh, A., Faudoa, E., Bretón‐Romero, R., El-Adili, F., Bujor, A. M., & Sam, F. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008372 · Cited by 36
Wei, S., Li, J., He, H., Shu, C., Dardik, A., & Bai, H. (2021) · Smart Materials in Medicine · doi:10.1016/j.smaim.2021.12.005 · Cited by 30
Chen, L., Wang, G., He, J., Yang, X. P., Zheng, Z., Deng, Y. J., Liu, Y., Chen, D., Lin, R., & Wang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108240 · Cited by 22
Huang, N., Zhu, T., Liu, T., Ge, X.-Y., Wang, D., Liu, H., Zhu, G.-X., Zhang, Z., & Hu, C.-P. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174307 · Cited by 21
Jensen, D. M., Skovsted, G. F., Bonde, M. F. B., Bentzon, J. F., Rolin, B., Franck, G., Ougaard, M. K., Voetmann, L. M., Bachmann, J. C., Uryga, A., et al. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.004 · Cited by 20
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Mimouni, M., Lajoix, A., & Desmetz, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010382 · Cited by 17
Akhtar, S., & Sharma, A. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2020.1866568 · Cited by 16
Zhang, W., Li, X., Li, M., He, H., Yang, C., Wang, M., Liu, D., Zhang, L., & Shu, C. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175826 · Cited by 14
Endothelial to mesenchymal cell transition in diabetic retinopathy: targets and therapeutics
Nijim, W., Moustafa, M., Humble, J., & Al‐Shabrawey, M. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1230581 · Cited by 15
Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12
Byford, A. R., Fakonti, G., Shao, Z., Soni, S., Earle, S. L., Bajarwan, M., Morley, L. C., Holder, B. S., SCOTT, E. M., & Forbes, K. A. (2025) · The Journal of Physiology · doi:10.1113/jp287931 · Cited by 13
Qian, J., Luo, W., Dai, C., Wang, J., Guan, X., Zou, C., Chattipakorn, N., Wu, G., Huang, W., & Liang, G. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166043 · Cited by 11
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
Shi, L., Xu, Y., Zhao, C., Qu, G., & Hao, M. (2024) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-024-00947-7 · Cited by 8
SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review
Caturano, A., D’Ardes, D., Simeone, P., Lessiani, G., Gregorio, N. D., Andreetto, L., Grassi, D., Serra, C., Santilli, F., Guagnano, M. T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155549 · Cited by 10
Yao, Q., Liu, H., Wang, X., Zhang, Z., Xie, H., Xie, C., & Gao, H. (2026) · Biological Research · doi:10.1186/s40659-025-00665-8 · Cited by 6
Kang, H. L., Várkonyi, Á., Csonka, Á., Szász, A., Várkonyi, T. T., Pósa, A., & Kupai, K. (2025) · Biomedicines · doi:10.3390/biomedicines13051148 · Cited by 3
Xiao, J., Yu, C. M., Chen, D., Lin, F., Zhang, S., Luo, D., & Zeng, E. (2026) · Molecular Biology Reports · doi:10.1007/s11033-025-11425-y · Cited by 2
Xie, W., Wu, F., He, J., Chen, S., Chen, L., Zhang, X., Sun, J., Liu, X., & Tao, J. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0364-y · Cited by 3
Self-citationXu, J., Zhu, L., Zhao, T., Wu, W., Chen, K., Fu, W., Zhang, H., Wang, X., & Zhang, J. (2025) · Research Square · doi:10.21203/rs.3.rs-6196928/v1 · Cited by 2
Liu, L. J., & Chu, Q. (2026) · Journal of Engineering and Science in Medical Diagnostics and Therapy · doi:10.1115/1.4070794
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Metadata
- Authors
- Tsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y.
- Affiliations
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Corresponding author
- Chen, Wei-Yu
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-06-14
- Volume
- 8
- Issue
- 6
- Pages
- 589
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6628350
- OpenAlex
- W2950515961
- Cited by
- 37
- References
- 62
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 9 · 2020: 3 · 2019: 1
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Chang Gung Medical Foundation (CMRPG8E1151, CMRPG8F0351, CMRPG8B0601, CMRPG8D0231-3, CMRPG8E0661-3, CMRPG8F1831, CMRPG8F1681, CMRPG8G1371, CMRPG8G1541)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- liraglutide, endothelial-to-mesenchymal transition, neointima formation, diabetic vascular complications, hyperglycemia, endothelial dysfunction, re-endothelialization, carotid artery, streptozotocin-induced diabetes, GLP-1 receptor agonists, ALK5 inhibition, SB431542, AMPK signaling, human umbilical vein endothelial cells
- MeSH terms
- Liraglutide, Snail Family Transcription Factors, Adenylate Kinase, Animals, Arteries, Diabetes Mellitus, Experimental, Endothelium, Glucose, Humans, Mesoderm, Mice, Inbred C57BL, Mice, Transgenic, RNA, Messenger, Streptozocin, Signal Transduction, Biomarkers, Smad2 Protein, Glucagon-Like Peptide 1, Interleukin-1beta, Neointima, Human Umbilical Vein Endothelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.